Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T43920
(Former ID: TTDS00304)
|
|||||
Target Name |
Carbonic anhydrase (CA)
|
|||||
Synonyms |
Carbonate dehydratase
Click to Show/Hide
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 3 Target-related Diseases | + | ||||
1 | Bacterial infection [ICD-11: 1A00-1C4Z] | |||||
2 | Hypertension [ICD-11: BA00-BA04] | |||||
3 | Seborrhoeic dermatitis [ICD-11: EA81] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 3 Approved Drugs | + | ||||
1 | Quinethazone | Drug Info | Approved | Hypertension | [2], [3], [4] | |
2 | Salicyclic acid | Drug Info | Approved | Seborrhoeic dermatitis | [4], [5], [6] | |
3 | Sulfamylon | Drug Info | Approved | Bacterial infection | [4], [7] | |
Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
1 | Curcumin | Drug Info | Phase 3 | Solid tumour/cancer | [8], [9] | |
2 | Phentermine+topiramate | Drug Info | Phase 3 | Obesity | [10] | |
3 | Coumate | Drug Info | Phase 2 | Breast cancer | [11] | |
Patented Agent(s) | [+] 2 Patented Agents | + | ||||
1 | Imatinib and nilotinib derivative 1 | Drug Info | Patented | Cas mediated disorder | [12] | |
2 | Imatinib and nilotinib derivative 2 | Drug Info | Patented | Cas mediated disorder | [12] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 123 Inhibitor drugs | + | ||||
1 | Quinethazone | Drug Info | [1] | |||
2 | Salicyclic acid | Drug Info | [13] | |||
3 | Sulfamylon | Drug Info | [14] | |||
4 | Curcumin | Drug Info | [15] | |||
5 | PARABEN | Drug Info | [16] | |||
6 | Phentermine+topiramate | Drug Info | [17] | |||
7 | PHENOL | Drug Info | [15] | |||
8 | Coumate | Drug Info | [18] | |||
9 | SULFAMIDE | Drug Info | [19] | |||
10 | FERULIC ACID | Drug Info | [16] | |||
11 | Imatinib and nilotinib derivative 1 | Drug Info | [12] | |||
12 | Imatinib and nilotinib derivative 2 | Drug Info | [12] | |||
13 | PMID30074415-Compound-19 | Drug Info | [12] | |||
14 | PMID30074415-Compound-20 | Drug Info | [12] | |||
15 | PMID30074415-Compound-21 | Drug Info | [12] | |||
16 | CLIOQUINOL | Drug Info | [13] | |||
17 | SPERMINE | Drug Info | [20] | |||
18 | (2-bromophenyl)difluoromethanesulfonamide | Drug Info | [21] | |||
19 | (4-bromophenyl)difluoromethanesulfonamide | Drug Info | [21] | |||
20 | 1-(3,4-dichlorophenyl)-3-hydroxyurea | Drug Info | [22] | |||
21 | 2,3-dihydro-1H-indene-5-sulfonamide | Drug Info | [23] | |||
22 | 2,4-Disulfamyltrifluoromethylaniline | Drug Info | [14] | |||
23 | 2,5-difluorophenol | Drug Info | [24] | |||
24 | 2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid | Drug Info | [23] | |||
25 | 2-amino-2,3-dihydro-1H-indene-5-sulfonamide | Drug Info | [23] | |||
26 | 2-Amino-benzenesulfonamide | Drug Info | [14] | |||
27 | 2-Amino-indan-5-sulfonic acid | Drug Info | [23] | |||
28 | 2-hydrazinylbenzenesulfonamide | Drug Info | [14] | |||
29 | 2-oxo-2H-chromene-3-carboxylic acid | Drug Info | [25] | |||
30 | 2-oxo-2H-thiochromene-3-carboxylic acid | Drug Info | [25] | |||
31 | 2-Sulfhydryl-Ethanol | Drug Info | [26] | |||
32 | 3,5-difluorophenol | Drug Info | [13] | |||
33 | 3-(4-sulfamoylphenyl)propanoic acid | Drug Info | [27] | |||
34 | 3-Amino-benzenesulfonamide | Drug Info | [28] | |||
35 | 3-bromophenyl-difluoromethanesulfonamide | Drug Info | [21] | |||
36 | 3-Nitro-benzenesulfonamide | Drug Info | [29] | |||
37 | 4-(2-AMINOETHYL)BENZENESULFONAMIDE | Drug Info | [30] | |||
38 | 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide | Drug Info | [14] | |||
39 | 4-(2-Hydroxy-ethyl)-benzenesulfonamide | Drug Info | [14] | |||
40 | 4-(2-Phenylacetamido)-3-bromobenzenesulfonamide | Drug Info | [31] | |||
41 | 4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide | Drug Info | [31] | |||
42 | 4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide | Drug Info | [31] | |||
43 | 4-(2-Phenylacetamido)benzenesulfonamide | Drug Info | [31] | |||
44 | 4-(2-Phenylacetamidoethyl)benzenesulfonamide | Drug Info | [31] | |||
45 | 4-(2-Phenylacetamidomethyl)benzenesulfonamide | Drug Info | [31] | |||
46 | 4-(2-Pyridin-2-ylacetamido)benzenesulfonamide | Drug Info | [31] | |||
47 | 4-(2-Pyridin-4-ylacetamido)benzenesulfonamide | Drug Info | [31] | |||
48 | 4-(hydroxymethyl)benzenesulfonamide | Drug Info | [14] | |||
49 | 4-amino-3,5-dibromobenzenesulfonamide | Drug Info | [32] | |||
50 | 4-Amino-3-bromo-benzenesulfonamide | Drug Info | [14] | |||
51 | 4-Amino-3-chloro-benzenesulfonamide | Drug Info | [14] | |||
52 | 4-amino-3-fluoro-5-iodobenzenesulfonamide | Drug Info | [32] | |||
53 | 4-Amino-3-fluoro-benzenesulfonamide | Drug Info | [14] | |||
54 | 4-Amino-3-iodo-benzenesulfonamide | Drug Info | [14] | |||
55 | 4-amino-6-chlorobenzene-1,3-disulfonamide | Drug Info | [14] | |||
56 | 4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide | Drug Info | [14] | |||
57 | 4-AMINOPHENOL | Drug Info | [24] | |||
58 | 4-azidobenzenesulfonamide | Drug Info | [33] | |||
59 | 4-bromophenylboronic acid | Drug Info | [34] | |||
60 | 4-butylphenylboronic acid | Drug Info | [34] | |||
61 | 4-CYANOPHENOL | Drug Info | [24] | |||
62 | 4-Hydrazino-benzenesulfonamide | Drug Info | [14] | |||
63 | 4-methoxyphenylboronic acid | Drug Info | [34] | |||
64 | 4-methylphenyl-difluoromethanesulfonamide | Drug Info | [21] | |||
65 | 4-Nitro-benzenesulfonamide | Drug Info | [29] | |||
66 | 4-nitrophenyl phosphate | Drug Info | [35] | |||
67 | 4-nitrophenyl-difluoromethanesulfonamide | Drug Info | [21] | |||
68 | 4-phenoxyphenylboronic acid | Drug Info | [34] | |||
69 | 4-Thiocyanato-benzenesulfonamide | Drug Info | [29] | |||
70 | 4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide | Drug Info | [31] | |||
71 | 4-[2-(2-Thienyl)acetamido]benzenesulfonamide | Drug Info | [31] | |||
72 | 6-(aminomethyl)-2H-chromen-2-one | Drug Info | [25] | |||
73 | 6-(hydroxymethyl)-2H-chromen-2-one | Drug Info | [25] | |||
74 | 6-Hydroxy-benzothiazole-2-sulfonic acid amide | Drug Info | [14] | |||
75 | 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid | Drug Info | [25] | |||
76 | 6-methyl-2-oxo-2H-chromene-3-carboxylic acid | Drug Info | [25] | |||
77 | 7-(benzyloxy)-2H-chromen-2-one | Drug Info | [25] | |||
78 | 7-butoxy-2H-chromen-2-one | Drug Info | [25] | |||
79 | 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid | Drug Info | [25] | |||
80 | 7-phenethoxy-2H-chromen-2-one | Drug Info | [25] | |||
81 | 7-propoxy-2H-chromen-2-one | Drug Info | [25] | |||
82 | 8-methoxy-2-oxo-2H-chromene-3-carboxylic acid | Drug Info | [25] | |||
83 | BENZOLAMIDE | Drug Info | [14] | |||
84 | Benzothiazole-2-sulfonic acid amide | Drug Info | [30] | |||
85 | Beta-naphthylboronic acid | Drug Info | [34] | |||
86 | Biphenyl-4-ylboronic acid | Drug Info | [34] | |||
87 | Carzenide | Drug Info | [14] | |||
88 | CATECHIN | Drug Info | [15] | |||
89 | CATECHOL | Drug Info | [16] | |||
90 | CL-5343 | Drug Info | [36] | |||
91 | COUMARIN | Drug Info | [25] | |||
92 | Decane-1,10-diyl disulfamate | Drug Info | [37] | |||
93 | Decyl sulfamate | Drug Info | [37] | |||
94 | ELLAGIC ACID | Drug Info | [16] | |||
95 | ETHOXYCOUMARIN | Drug Info | [25] | |||
96 | Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate | Drug Info | [25] | |||
97 | GALLICACID | Drug Info | [16] | |||
98 | HERNIARIN | Drug Info | [25] | |||
99 | Hexane-1,6-diamine | Drug Info | [20] | |||
100 | N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide | Drug Info | [38] | |||
101 | N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide | Drug Info | [38] | |||
102 | N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide | Drug Info | [38] | |||
103 | N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide | Drug Info | [38] | |||
104 | N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide | Drug Info | [38] | |||
105 | N1-(2-aminoethyl)ethane-1,2-diamine | Drug Info | [20] | |||
106 | N1-(naphthalen-1-yl)ethane-1,2-diamine | Drug Info | [20] | |||
107 | Octane-1,8-diyl disulfamate | Drug Info | [37] | |||
108 | Octyl sulfamate | Drug Info | [37] | |||
109 | P-Coumaric Acid | Drug Info | [16] | |||
110 | P-toluenesulfonamide | Drug Info | [14] | |||
111 | P-tolylboronic acid | Drug Info | [34] | |||
112 | PARAOXON | Drug Info | [35] | |||
113 | Pentane-1,5-diamine | Drug Info | [20] | |||
114 | Phenyl Boronic acid | Drug Info | [39] | |||
115 | Phenylarsonic acid | Drug Info | [39] | |||
116 | PHENYLDIFLUOROMETHANESULFONAMIDE | Drug Info | [21] | |||
117 | PHENYLMETHANESULFONAMIDE | Drug Info | [21] | |||
118 | PRONTOCIL | Drug Info | [32] | |||
119 | RESORCINOL | Drug Info | [24] | |||
120 | SACCHARIN | Drug Info | [40] | |||
121 | Sodium maleate | Drug Info | [41] | |||
122 | SULFAMATE | Drug Info | [39] | |||
123 | Syringic Acid | Drug Info | [16] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation | ||||||
Target QSAR Model |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73. | |||||
REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7289). | |||||
REF 3 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 013264. | |||||
REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4306). | |||||
REF 6 | Drug information of Salicyclic acid, 2008. eduDrugs. | |||||
REF 7 | ClinicalTrials.gov (NCT00634166) Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group. U.S. National Institutes of Health. | |||||
REF 8 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7000). | |||||
REF 9 | Nanocurcumin: a promising therapeutic advancement over native curcumin. Crit Rev Ther Drug Carrier Syst. 2013;30(4):331-68. | |||||
REF 10 | Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy. J Clin Pharm Ther. 2008 Oct;33(5):513-9. | |||||
REF 11 | Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. Expert Rev Anticancer Ther. 2011 Feb;11(2):179-83. | |||||
REF 12 | Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. | |||||
REF 13 | Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6. | |||||
REF 14 | Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. | |||||
REF 15 | Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. | |||||
REF 16 | Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. | |||||
REF 17 | Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. | |||||
REF 18 | Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. | |||||
REF 19 | Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5. | |||||
REF 20 | Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. | |||||
REF 21 | Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. | |||||
REF 22 | N-hydroxyurea--a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4316-20. | |||||
REF 23 | Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. | |||||
REF 24 | Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. | |||||
REF 25 | Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. | |||||
REF 26 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
REF 27 | Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides. Bioorg Med Chem. 2009 Jul 1;17(13):4503-9. | |||||
REF 28 | Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6001-6. | |||||
REF 29 | Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7. | |||||
REF 30 | Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):971-6. | |||||
REF 31 | Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. | |||||
REF 32 | Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. | |||||
REF 33 | Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4624-7. | |||||
REF 34 | Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. | |||||
REF 35 | Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12. | |||||
REF 36 | Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81. | |||||
REF 37 | Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. | |||||
REF 38 | Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. | |||||
REF 39 | Carbonic anhydrase inhibitors: inhibition of the cytosolic human isozyme VII with anions. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3139-43. | |||||
REF 40 | Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54. | |||||
REF 41 | Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with ali... Bioorg Med Chem. 2009 Apr 1;17(7):2654-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.